{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-034971","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.536446+00:00","generated_at":"2026-05-18T06:32:32.199813+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Prime Medicine CSO Jeremy Duffield steps down effective July 15, 2025; retains as consultant through Mar 2026","bullets":["Jeremy Duffield, M.D., Ph.D., FRCP, resigns as Chief Scientific Officer effective July 15, 2025.","Company to enter Separation Agreement providing severance per his 2022 employment agreement.","Duffield retained as consultant from July 15, 2025 through March 31, 2026.","All outstanding equity awards continue vesting during the Advisory Period.","No successor named in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-034971","json":"https://secwatch.observer/filing/0001628280-25-034971.json","markdown":"https://secwatch.observer/filing/0001628280-25-034971.md","text":"https://secwatch.observer/filing/0001628280-25-034971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025034971/0001628280-25-034971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025034971/prme-20250714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:32:32.199813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}